Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

David A. Nathanson, Ph.D.
David A. Nathanson, Ph.D.

Affiliation(s):

Assistant Professor, Department of Molecular and Medical Pharmacology
Member, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research
Member, JCCC Signal Transduction and Therapeutics Program Area

Contact Information:

Phone:
(310) 825-8813
Email:

Scientific Interest(s):

Dr. David Nathanson’s laboratory focuses on glioblastoma (GBM), the most lethal form of brain cancer. The Nathanson lab has specific interest in investigating altered signal transduction networks and the interplay with GBM metabolism, with a strong emphasis on metabolic phenotyping of specific oncogenic signals using non-invasive positron emission tomography (PET). In addition, they are interested in understanding the mechanisms of resistance to targeted therapies in GBM, including intrinsic adaptive signaling and the role of tumor heterogeneity. Their ultimate goal is to develop new strategies 1) to use metabolic PET to non-invasively measure oncogene activity for drug development/dosing and 2) to predict and exploit tumor adaptation to targeted therapies.

Selected Cancer-Related Publications:

Nathanson DA, Armijo AL, Tom M, Li Z, Dimitrova E, Austin WR, Nomme J, Campbell DO, Ta L, Le TM, Lee JT, Darvish R, Gordin A, Wei L, Liao HI, Wilks M, Martin C, Sadeghi S, Murphy JM, Boulos N, Phelps ME, Faull KF, Herschman HR, Jung ME, Czernin J, Lavie A, Radu CG. Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication. J Exp Med. 2014 Mar 10;211(3):473-86. doi: 10.1084/jem.20131738. Epub 2014 Feb 24.

Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, Reed R, Nelson SF, Cloughesy TF, James CD, Rao PN, Kornblum HI, Heath JR, Cavenee WK, Furnari FB, Mischel PS. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014 Jan 3;343(6166):72-6. doi: 10.1126/science.1241328. Epub 2013 Dec 5.

Wang J, Hwang K, Braas D, Dooraghi A, Nathanson D, Campbell DO, Gu Y, Sandberg T, Mischel P, Radu C, Chatziioannou AF, Phelps ME, Christofk H, Heath JR. Fast metabolic response to drug intervention through analysis on a miniaturized, highly integrated molecular imaging system. J Nucl Med. 2013 Oct;54(10):1820-4. doi: 10.2967/jnumed.112.118497. Epub 2013 Aug 26.

Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, Yang H, Tanaka K, Oba-Shinjo SM, Uno M, Inda MM, Wykosky J, Bachoo RM, James CD, DePinho RA, Vandenberg SR, Zhou H, Marie SK, Mischel PS, Cavenee WK, Furnari FB. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14164-9. doi: 10.1073/pnas.1211962109. Epub 2012 Aug 13.

Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, Yong WH, Vinters HV, Gera JF, Cavenee WK, Cloughesy TF, Manning BD, Baldwin AS, Mischel PS. Oncogenic EGFR signaling activates an mTORC2-NF-KappaB pathway that promotes chemotherapy resistance. Cancer Discov. 2011 Nov;1(6):524-38. doi: 10.1158/2159-8290.CD-11-0124. Epub 2011 Sep 13.